**METHODS**

**ONCERVIR** is a Phase 3, multicenter, double-blind, randomized, controlled clinical trial (ONCERVIR) in HIV-1–infected, treatment-naïve males and females ≥18 years of age with HIV-1 RNA >1000 copies/mL.

**Baseline Characteristics**

- **Key entry criteria**
  - Age in years, mean (SD)
  - In combination with TDF/FTC QD.

**Efficacy Outcomes**

- **Virologic efficacy**
  - Proportion of participants achieving HIV-1 RNA <40 copies/mL.

**Safety**

- **Summary of AEs**
  - Drug-related and serious drug-related AEs
  - Discontinued study due to AE

**RESULTS**

- **Safety Analyses**
  - Overall safety profile was similar to that of RAL 400 mg BID

**DISCUSSION**

- **Summary of Clinical Relevance**
  - The results of this study provide evidence of the potential benefits of RAL 1200 mg QD, in combination with TDF/FTC, in the treatment of HIV-1 infection.

**CONCLUSIONS**

- **Summary of Findings**
  - The results of this study provide evidence of the potential benefits of RAL 1200 mg QD, in combination with TDF/FTC, in the treatment of HIV-1 infection.